Itezocabtagene autoleucel is under clinical development by Tessa Therapeutics and currently in Phase I for Natural Killer Cell Lymphomas. According to GlobalData, Phase I drugs for Natural Killer Cell Lymphomas have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Itezocabtagene autoleucel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Itezocabtagene autoleucel overview

Itezocabtagene autoleucel (TT-11) is under investigation for the treatment of relapsed/refractory Hodgkin's lymphoma and non-Hodgkin's lymphoma, anaplastic large cell lymphoma, peripheral T cell lymphoma, extranodal natural killer cell lymphomas /T-cell lymphoma, diffuse large B cell lymphoma and primary mediastinal large B-cell lymphoma (PMBCL). The therapeutic candidate is administered as intravenous injection. It comprises of CTLs genetically modified with EBVs to express chimeric antigen receptors targeting CD30L receptors.

Tessa Therapeutics overview

Tessa Therapeutics is a clinical-stage biotechnology company that discovers, develops, and commercializes cancer immunotherapies that redirect the body’s powerful anti-viral immune response and identify and exterminate cancer cells. The company provides products for cancers including gastric carcinoma, cervical, nasopharyngeal, head, oropharyngeal, and neck cancer. It harnesses virus-specific T cell (VST) technology for the treatment of solid tumors. Tessa Therapeutics is also extending its VST platform and treat an array of solid tumors through combinatorial approaches with chimeric antigen receptors, antibodies, and oncolytic virus technologies. The company works in partnership with National Cancer Centre, Singapore, Baylor College of Medicine, and Agency for Science, Technology and Research. Tessa Therapeutics is headquartered in Singapore.

For a complete picture of Itezocabtagene autoleucel’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 April 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.